REFERENCES
- Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316: 73–78
- Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol. 1991; 1: 990–998
- Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40: 110–118
- Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl. 2)1–47
- Smrzova J, Balla J, Barany P. Inflammation and resistance to erythropoiesis-stimulating agents—what do we know and what needs to be clarified?. Nephrol Dial Transplant. 2005; 20(Suppl. 8)2–7
- Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol. 1997; 8: 1921–1929
- Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant. 2002; 17(Suppl. 1)48–52
- Perez-Garcia R, Rodriguez-Benitez P, Villaverde MT, Valderrabano F. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?]. Nefrologia. 2001; 21: 606–607
- Molina M, Garcia Hernandez MA, Navarro MJ, De Gracia MC, Ortuno T. [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha]. Nefrologia. 2004; 24: 564–571
- Molina M, Navarro MJ, Palacios ME, et al. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving hemodialysis]. Nefrologia. 2007; 27: 196–201
- Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007; 22: 794–800
- Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003; 31: 290–299
- Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant. 2007; 22(Suppl. 4)19–30
- Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous darbepoetin alfa administered once every two weeks in chronic kidney disease patients on hemodialysis. Nephrol Dial Transplant. 2006; 21: 2846–2850
- Aranesp®. Summary of product characteristics. BredaThe Netherlands 2006, Amgen Europe B.V.,